Hepatocellular carcinoma (HCC) is a common and deadly cancer. Most cases of HCC arise in a cirrhotic/fibrotic liver, indicating that environment may play a paramount role in cancer genesis. Previous studies from our group and others have shown that, in desmoplastic cancers, there is a rich intercellular communication between activated, cancer-associated fibroblasts and cancer cells. Moreover, extracellular vesicles (EVs), or exosomes, have been identified as an important arm of this intercellular communication platform. Finally, these studies have shown that EVs can carry microRNA (miR) species in vivo and deliver them to desmoplastic cancers. The precise role played by activated liver fibroblasts/stellate cells in HCC development is insufficiently known. Based on previous studies, it appears plausible that activated fibroblasts produce signals carried by EVs that promote HCC genesis. In the current study, we first hypothesized and then demonstrated that stellate cell-derived EVs 1) can be loaded with an miR species of choice (miR-335-5p); 2) are taken up by HCC cells in vitro and more importantly in vivo; 3) can supply the miR-335-5p cargo to recipient HCC cells in vitro as well as in vivo; and 4) inhibit HCC cell proliferation and invasion in vitro as well as induce HCC tumor shrinkage in vivo. Finally, we identified messenger RNA targets for miR-335 that are downregulated after treatment with EV-miR-335-5p. This study informs potential therapeutic strategies in HCC, whereby stellate cell-derived EVs are loaded with therapeutic nucleic acids and delivered in vivo. (HEPATOLOGY 2018;67:940-954) 
H epatocellular carcinoma (HCC) ranks as the third most common cause of cancer-related death worldwide.
(1) Importantly, the vast majority of HCCs develop in a background of liver fibrosis or cirrhosis. (2) Liver fibrosis is produced when inactive liver fibroblasts (stellate cells) become activated after liver injury and turn into collagen-producing cells. (3) In desmoplastic cancers, cancer-associated fibroblasts (CAFs) are loosely defined as fibroblasts found within the tumor mass. These CAFs have been implicated as etiologic players both in the cancer genesis and homeostasis. (4, 5) These data appear to suggest that liver fibrosis, or activated stellate cells, play a role in the development of HCC, perhaps similar to the role played by CAFs in desmoplastic cancers.
The origin of activated fibroblasts in HCC remains controversial. Recent studies have revealed multiple potential origins, including activation of stellate cells or portal fibroblasts or transdifferentiation of hepatocytes through epithelial to mesenchymal transition. (6, 7) In a previous study, we identified microRNA (miR) species down-regulated in human liver stellate (LX2) cells by coculturing them with cholangiocarcinoma cells. (8) Interestingly, there is a significant overlap between the list of miR species found to be down-regulated in LX2 cells placed in coculture with cancer cells (arguably promoting their CAF phenotype) and miR species identified to be down-regulated in the same cells during the transition from retinol-containing inactive stellate cells to activated, collagen-producing cells. (9) (10) (11) It is therefore formally possible that the transition from inactive stellate cells to activated cells to CAF is a continuum of relevance in HCC development. By extension, this scenario suggests that activated stellate cells/ liver fibroblasts are active participants in the development of HCC. The precise nature of the interactions between liver cancer cells and the rest of the cells in the cancer environment are under intense investigation. For example, in cholangiocarcinoma, we have previously shown that fibroblasts and cancer cells communicate via EVs. (8) Moreover, we have shown that stellate cell-derived EVs are taken up by cancer cells in vitro and in vivo. (8) Last, and of high clinical interest, we have shown that we can manipulate in vitro EVs derived from these stellate cells to efficiently carry an miR cargo to cholangiocarcinoma in vivo, shrink tumors and increase survival in a rat cholangiocarcinoma model. (8) We concluded that disrupting the cross-talk between liver fibroblasts/activated stellate cells/CAFs and cancer cells may potentially open a novel avenue to improve clinical outcomes.
The current study is based on the hypothesis that stellate cell-derived EVs can be delivered to HCC cells in vitro and in vivo, and that they can inhibit cancer growth when carrying a therapeutic miR cargo. Here, we demonstrated that EVs loaded with miR-335-5p (EV-miR-335) can decrease cancer growth and invasion in vitro and in vivo. We have also shown that EV-miR-335-5p can be used successfully in vivo to induce HCC shrinking. Last, we identified messenger RNA (mRNA) targets for miR-335 that are down-regulated following treatments with EV-miR-335. These mRNA species are likely downstream effectors of EV-miR-335 treatment.
Materials and Methods
Additional information can be found in the Supporting Information.
CELL LINES AND COCULTURE CONDITIONS
Four human hepatocellular carcinoma cells: MHCC97H, MHCC97L, HepG2, and Huh7, as well as human hepatic stellate (LX2) cells, were maintained in Dulbecco's modified Eagle's medium (Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA), 100 U/mL penicillin G, and 100 mg/mL streptomycin (Quality Biological, Gaithersburg, MD) at 378C in a humidified chamber with 95% air and 5% CO 2 .
PLASMID TRANSFECTION AND VIRUS INFECTION
pCDH-EF1-MCS-IRES-GFP complementary DNA (cDNA) Cloning and Expression Vector (HIV) (System Biosciences, CD530A-2-SBI) (7.5 mg/ 10 cm plate), PxPAX2 expressing HIV gag/pol, Rev, and tat (6 mg/10 cm plate; Addgene, Cambridge, MA), and pMD2.G vector expressing VSV.G (2 mg/ 10 cm plate) were transfected into two 100-mm culture dishes of 293T cells using X-tremeGENE HP DNA transfection reagent (Roche, Basel, Switzerland). Seventy-two hours after transfection, supernatant was collected. HCC cells were transduced with the viral supernatant, and green fluorescent protein (GFP)-positive cells were sorted with BD FACSJazz (BD Biosciences, San Jose, CA).
ESTABLISHMENT OF loxp-dsRedloxp-Stop-eGFP-puro-WPRE CONSTRUCTS FOR EACH OF THE FOUR HCC CELL LINES
PMSC-loxp-dsRed-loxp-Stop-eGFP-puro-WPRE (Addgene plasmid, 7.5 mg/10 cm plate) gag/pol plasmid (6 mg/10 cm plate) (Addgene), and VSV-G vector (2 mg/10 cm plate) were transfected into
four 100-mm culture dishes of 293T cells using XtremeGENE HP DNA transfection reagent (Roche). Seventy-two hours after transfection, supernatant was collected.
HCC cells were transduced with virus supernatant. Seventy-two hours later, cells were treated with puromycin (9 mg/mL for MHCC97H, MHCC97L, HepG2, and 7 mg/mL for Huh7) for 2 weeks.
EXOSOME ISOLATION AND CHARACTERIZATION
Exosomes were isolated and characterized as described previously. (8) 
EXOSOMES TRANSFECTION WITH miR-335-5p MIMICS OR miR-NONSPECIFIC MIMIC
Exosomes from LX2 cells were transfected with miR-335-5p mimics or miR-nonspecific mimic (NSM) as described previously. (8) Specifically, the EVs were transfected with miR-335-5p or NSM using lipofectamine RNAiMAX reagent (ThermoFisher, Waltham, MA). Specifically, to transfect 30 mg exosomes, we used 2 mL Lipofectamine RNAiMAX Reagent diluted in 25 mL Opti-MEM medium (OM), and 1 mL miR-335-5p mimic or NSM (10 pmol) diluted in 25 mL Opti-MEM medium. Then we mixed the diluted lipofectamine RNAiMAX reagent and diluted miR-335-5p mimic or NSM and incubated for 5 minutes at room temperature. Isolated EVs were diluted in 250 lL Opti-MEM medium, then the miRNA-lipid complexes were added to the diluted EVs and incubated for 6 hours at 378C. Then, EV-miR-335 or EV-NSM were concentrated with Vivaspin 2 purification column (50 kDa, GE Healthcare, UK). Real-time polymerase chain reaction (PCR) with miR-335-5p primers identified in excess of 6000-fold more miR-335-5p when EVs were present, suggesting that all miR-335-5p is associated with EVs and almost nothing exists outside of EVs (Supporting Figure S1 ).
DETECTION OF Cre mRNA EXPRESSION IN EVs
LX2 cells were transfected with Cre as described above. EVs were isolatedfrom cell-conditionedmedia usinghighspeed centrifugation. RNA was isolated from cells, cellconditioned media, and supernatant) using the Trizol reagent (Ambion; Life Technologies, Carlsbad, CA) according to the manufacturer's instructions. The amount and purity of isolated RNA was analyzed with a Nanodrop spectrophotometer (Nano Drop Technologies, Wilmington, DE). Reverse transcription was performed using the TaqManMicroRNAReverseTranscriptkit(AppliedBiosystems, Foster City, CA). The resulting cDNA was then amplifiedinaPCRreactionusingCre-specificprimers(forwardprimer:5 0 -GCCTGCATTACCGGTCGATGC-3 0 ; reverse primer: 5 0 -GTGG CAGATGGCGCGG-CAACA-3 0 ). Thermal cycle conditions used for all reactionswereasfollows:5minutesat958C,followedby35cycles consistingofdenaturationfor30secondsat958C,annealing for 30 seconds at 588C, and extension for 1 minute at 728C. PCR reactions were concluded with incubation for 10 minutesat728Ctocompletetheextensionofallsynthesized products. PCR products were then visualized on a 1.25% TAEagarosegel(SupportingFigureS2).
IN VITRO DETECTION OF EXOSOME TRANSFER
MHCC97L cells were stably transfected with PMSC-loxp-dsRed-loxp-Stop-eGFP-puro-WPRE, then, exosomes from LX2-Cre cell or control LX2 cells were added to the medium of 97L-loxp-dsRedloxp-Stop-eGFP. The medium was not changed for 72 hours to allow LX2 exosomes carrying Cre to be taken up by MHCC97L cells. The successful packaging of Cre into EVs by LX2 cells, followed by the successful uptake of these exosomes by MHCC97L and, finally, use of Cre by these cancer cells would result in a deletion event between the two loxp sites of MHCC97L. This deletion event would in turn cause the excision of dsRed (red) and expression of GFP (green).
IN VIVO DETECTION OF EXOSOME TRANSFER
MHCC97H cells were stably transfected with PMSC-loxp-dsRed-loxp-Stop-eGFP-puro-WPRE as described above. These 97H-loxp cells (2 3 10 6 ) were injected subcutaneously into female NOD scid gamma mice (The Jackson Laboratory, Bar Harbor, ME) at the age of 6 weeks to establish tumors. After 1 week, exosomes from LX2-Cre medium were injected intratumorally. Tumors were harvested 7 days later. Expression of eGFP and dsRed were tested with western blot assay and immunofluorescence. The described animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee at the Johns Hopkins University.
MEASUREMENT OF LX2-EXOSOME-miR-335 EFFECTS ON MHCC97H SPHEROIDS
We generated MHCC97H spheroids by using the hanging drop method, which utilizes spheroids completely embedded in Matrigel as described in the Supporting Materials and Methods and by Berens et al. (12) Exosomes were transfected with miR-335-5p mimics or miR-NSM as described above. Then, 5 mg exosomes-miR-335 or exosomes-NSM per well were added in the medium on top of the spheroid. The invasion areas were measured with ImageJ software (National Institutes of Health, Bethesda, MD). The invasion index was calculated by dividing the invasion area by the area of the 24-hour spheroid.
MEASUREMENT OF LX2-EXOSOME-miR-335 EFFECTS ON MHCC97H CELL IN VIVO
MHCC97H cells (2 3 10 6 ) were injected subcutaneously into female NOD scid gamma mice (The Jackson Laboratory) at the age of 6 weeks, to establish tumors. When tumors were visible and grew to a length of 5 mm, exosomes were transfected with miR-335 or miR-NSM as above. Then, 50 mg exosomes per mouse (16.7 pmol miR-mimics) were injected intratumorally twice a week for 4 weeks. The greatest longitudinal diameter (length) and the greatest transverse diameter (width) of each tumor was determined. Tumor volume based on caliper measurements was calculated using a modified ellipsoidal formula (13, 14) : 1/2 (length 3 width 2 ).
QUANTITATIVE mRNA REVERSE-TRANSCRIPTION PCR USING TAQMAN HUMAN CANCER PATHWAY PANEL
MHCC97H and MHCC97L cells were transfected with miR-335-5p mimic or negative control. Total RNA was extracted from cultured cells using TRIzol reagent (Ambion; Life Technologies). In addition, RNA was extracted from mouse tumors treated with miR-335 or NSM, respectively. cDNA was synthesized with High-Capacity cDNA Reverse Transcription Kits (ThermoFisher), and quantitative reverse-transcription PCR (qRT-PCR) analysis was applied with specific Taqman Human Cancer pathway panels, which contains 624 genes related to DNA repair, angiogenesis, cell adhesion, and extracellular matrix (ECM), as well as genes involved in the cell cycle and apoptosis that have been found to be differentially expressed in early cancer and metastatic disease.
IMMUNOSTAINING OF Ki67 AND CLEAVED CASPASE-3 ON FROZEN SECTIONS
Mouse xenograft tumor tissue was harvested and prepared for frozen sectioning. The frozen sections were fixed and stained with Ki67 and cleaved caspase-3 antibodies (Sigma-Aldrich). The positive cells were counted with ImageJ software, and the relative ratio was calculated by dividing the total cells in the same view. Each experiment was repeated three times.
STATISTICAL METHODS
SPSS software version 17 (IBM, Armonk, NY) was used to perform statistical tests. Data are expressed as the mean 6 standard deviation. A paired Student t test was used to test the differences in sample means for data with normally distributed means. Statistical significance was assumed at P < 0.05.
Results

COCULTURING HCC CELLS WITH FIBROBLASTSLEADS TO DOWN-REGULATION OF miR-335-5p WITHIN FIBROBLASTS, AS WELL AS IN HCC CELLS
miR-335 has been implicated as a tumor suppressor miR species in HCC. (15) In addition, outside the liver, miR-335 overexpression suppresses metastatic colonization in human breast cancer lines. Conversely, the inhibition of miR-335 has the opposite effect, enhancing metastasis. (16) We concluded that, in some human cancers, and more importantly, in HCC, miR-335 acts as a tumor suppressor. In addition, further literature review uncovered a report of gradual miR-335 down-regulation along the continuum from inactive to activated human stellate cells. (11) These two lines of reported involvement of miR-335 in liver diseases suggested a scenario wherein liver fibrosis (activation of stellate cells) and cancer development may be characterized by downregulation of miR-335 both in stellate cells and in epithelial cancer cells. We chose to study miR-335-5p due to its reported cancer-suppressing and antifibrotic effects. In the current study, we focused on the delivery of miR-335-5p to HCC cells by using EVs. First, we assessed baseline levels of miR-335 in LX2 cells, as well as in several HCC cell lines when cultured individually. We found that the level of miR-335 was higher in LX2 cells cultured by themselves versus HepG2, MHCC97L, MHCC97H, and Huh7 liver cancer cells cultured by themselves (Fig. 1A) . Next, we investigated how miR-335-5p levels change when coculturing fibroblast cells (LX2) with each of the four cancer cell lines. HCC cells were stably transduced with pCDH-EF1-MCS-IRES-GFP lentivirus. These HCC cells expressed GFP for the purpose of FACS sorting after direct coculture with LX2 cells. Each of these four HCC cell lines were then directly cocultured with LX2 cells for 14 days. After coculturing, HCC cells and LX2 cells were separated by sorting according to GFP positivity. Of note, previous studies demonstrating downregulation of miR-335-5p in HCC as well as in activated stellate cells did not investigate whether the downregulation of miR-335-5p occurs concurrently when these two cell types are in direct contact (such as is the case in vivo or in direct coculture conditions). We hypothesized that an etiologic role for miR-335-5p in HCC development (particularly in a background of fibrosis) might be accompanied by simultaneous downregulation both in cancer cells and stromal cells. Remarkably, we found that miR-335 levels are downregulated in each of the four HCC cell lines upon coculturing with LX2 cells (Fig. 1B-E) . Moreover, we noted that miR-335-5p levels were also down-regulated in LX2 cells when cocultured with any of the HCC cell types (Fig. 1F) . These findings suggest that the symbiotic cancer cell-CAF environment appears to benefit from the down-regulation of miR-335-5p. Another possible implication is that miR-335-5p can be actively shuttled between the two cell types and therefore, the levels are in equilibrium. By extension, if these hypotheses are correct, the consequence would be that upregulating miR-335-5p in either of the two cell types would have similar phenotypic effects.
OVEREXPRESSION OF miR-335-5p IN HCC CELLS INHIBITS THEIR PROLIFERATION AND INVASION
To investigate the potential role of miR-335-5p in HCC growth and metastasis, HepG2, MHCC97H, MHCC97L, and Huh7 cells were transfected with miR-335-5p mimics and negative control (NSM). Next, we determined cancer cell proliferation by MTT assay and invasion by transwell assay. The proliferation assays showed that miR-335-5p restoration markedly inhibited cell growth in each of the four HCC cell lines tested ( Fig. 2A) when compared with control NSM-transfected cells. The transwell assay demonstrated significant cell invasion inhibition in the miR-335-5p-transfected cells compared with their control counterparts (Fig. 2B,C) . We conclude that miR-335-5p exerts its anticancer effects through by growth as well as invasion of HCC cells. 
UP-REGULATION OF miR-335-5p WITHIN FIBROBLASTS IS SUFFICIENT TO INHIBIT NEIGHBORING CANCER CELL PROLIFERATION, INVASION, AND MOTILITY
We transfected LX2 cells with miR-335-5p or NSM, respectively, then cocultured these cells with each of the following four HCC cell lines:HepG2, MHCC97H, MHCC97L, and Huh7. The number of cancer cells after 3 days was then assessed. We found that each of the 4 cancer cell lines proliferated less when cocultured with LX2 cells overexpressing miR-335 versus control (Fig. 3A) . We further explored the invasion ability of cancer cells when cocultured with LX2-miR-335-5p or LX2-NSM. We found that when cocultured with LX2 cells transfected with miR-335-5p, cancer cells invaded less versus control (Fig.   3B,C) . Similar results were obtained in a scratch assay, suggesting that the motility of HCC cells, including HepG2 (Fig. 4A,B) , MHCC97H (Fig. 4C,D) , MHCC97L (Fig. 4C, D) , and Huh7 (Fig. 4E,F) is inhibited when each individual cancer cell line is cocultured with LX2 cells overexpressing miR-335. We concluded that up-regulation of miR-335-5p in fibroblasts is sufficient to inhibit growth and invasion in neighboring cancer cells. This observation raises an important question: Is the observed phenotype due, at least in part, to miR transfer from fibroblasts to cancer cells?
EXOSOMAL TRANSFER FROM FIBROBLASTS TO HCC CELLS IN VITRO
It was previously reported by our group, as well as others, that EVs can transfer RNA between cells. The data presented above suggest that miR-335-5p might be actively shuttled between fibroblasts and cancer cells in our coculture system. To investigate this hypothesis, we employed the Cre-loxp system. First, EVs from LX2-Cre cells were isolated. As shown in Supporting Figure S2 and in previous studies, EVs from cells transfected with a Cre vector express Cre mRNA. (18) Next, we characterized LX2-derived EVs and found typical exosomal markers (Fig. 5A) . To further characterize these particles, we used nanoparticle tracking analysis. We found that the mean size of isolated EVs was approximately 100 nM, suggestive of a typical exosome size (Fig. 5B) . To determine whether miR-335-5p can be directly transferred from fibroblasts to HCC cells via EVs, we transfected HCC cells with PMSC-loxp-dsRed-loxp-Stop-eGFP-puro-WPRE retrovirus. After transfection and selection, HCC cells demonstrated, as expected, fluorescence in the red but not green channels (Supporting Figure  S32) . As an intermediary step, and to verify that LX2-Cre release EV-Cre in coculture, we directly cocultured LX2-Cre cells with HCC cells expressing loxpdsRed-loxp-Stop-eGFP. We surmised that if EVs carry Cre from LX2 cells to cocultured HCC cells, then we would note a change in fluorescence from red to green. Indeed, after 1 week of coculture, we noted that select cancer cells in culture switched fluorescence from the red to the green spectrum (Supporting Figure  S4) . Finally, we directly added exosomes isolated from LX2-Cre to MHCC97L-loxp-dsRed-loxpStop-eGFP for 1 week. We noted that select cancer cells have switched from red to green, demonstrating that 1) EVs carrying Cre were taken up by these cancer cells and 2) the EV cargo had been used within cancer cells (Fig. 5C ). We therefore concluded that EVs released from fibroblasts have the ability to shuttle their cargo from cells of origin (fibroblasts) to neighboring target cells (cancer cells).
EXOSOMAL DELIVERY TO HCC CELLS IN VIVO
To study the intercellular EV exchange in vivo, we first established xenograft subcutaneous tumors in NOD scid gamma mice with HepG2-loxp-dsRedloxp-Stop-eGFP, MHCC97H-loxp-dsRed-loxp-StopeGFP, and MHCC97L-loxp-dsRed-loxp-Stop-eGFP cells, respectively. After we successfully established tumor xenografts from each of these three HCC cell lines, we sought to inject EVs directly into these tumors and detect the use of EV cargo in the cytoplasm of cancer cells. Finally, to gain insight into the effects of a low dose of EVs, we decided to perform a single injection of EVs into tumors. To this end, we administered a single dose of exosomes (150 ng) from LX2-Cre by injection directly into the tumor mass. We surmised that if EVs injected in the cancer mass are taken up by cancer cells, even after a single dose, then we should see at least a few cancer cells switching from red to green fluorescence. Seven days later, the tumor tissue was harvested and proteins were isolated. GFP and dsRed proteins were detected by way of western blot analysis. As shown in Figure 5D , dsRed was detected in lysate from all tumors, whereas GFP was detected only in lysates from mouse tumors treated with EV-Cre. These data demonstrate that EV-Cre were taken up by cancer cells in vivo and their cargo was used within these cancer cells. To further verify our findings, we sought to detect GFP by an independent method. To this end, we performed immunofluorescence on cancer tissue slides, which showed that cancer cells within tumors treated with EV-Cre have taken up and utilized Cre (Fig. 5E ). In conclusion, 1) we gave mice a single dose of EVs (low dose, through direct tumor injection); 2) to ensure reproducibility, experiments were performed in xenografts established from three different cell lines; and 3) we detected a change in GFF/dsRed through two independent methods (western blotting and immunofluorescence).
miR-335-5p DELIVERED BY EVs INHIBITS HCC INVASION IN VITRO
While we have shown that 1) cancer cells grow less and invade less when co-cultured with fibroblasts overexpressing miR-335-5p; 2) EVs produced by fibroblasts can successfully deliver their cargo to cancer cells and 3) that cancer cells utilize the cargo delivered by EVs intra-cytoplasmatically, we had yet to demonstrate that miR-335 delivered by EVs had a phenotypic effect on target cancer cells. To this end, we generated cancer cell spheroids by employing the hanging-drop methodology, as described in Supporting Materials and Methods and in other published protocols. (12) The hanging drop methodology was implemented to obtain a 3D preclinical representation of cancer invasion capabilities. Spheroids were then treated with EVmiR-335 and EV-NSM, respectively. We noted MHCC97H spheroids treated with EV-miR-335-5p invaded the surrounding Matrigel significantly less versus spheroids treated with the control EV-NSM (Fig. 6A,B) .
miR-335-5p DELIVERED BY EVs INHIBITS HCC GROWTH IN VIVO
To further delineate whether EV transfer of fibroblast-derived miR-335-5p could impact HCC growth in vivo, MHCC97H cells (2 3 10 6 ) were injected subcutaneously into 6-week-old female NOD scid gamma mice. When tumors reached 5 mm in diameter, EVs that were transiently transfected with miR-335-5p or negative control were quantified. Next, 50 mg EV-miR-335-5p (16.7 pmol of miR-335-5p) per mouse were injected intratumorally twice a week for 4 weeks. We found that the EV treatment resulted in significantly smaller tumors in the treatment group versus control (Fig. 6C) . Similar findings were found when the animals were euthanized and the tumors were measured directly after excision (Fig. 6D,E) .To verify that, indeed, the levels of miR-335-5p are higher in tumors that grew less versus control tumors, we quantified its levels using qRT-PCR. We found that levels of miR-335-5p were approximately 30-fold higher in tumors that were treated with EV-miR-335 versus control (Fig. 6F) .
IN VIVO TREATMENT OF HCC WITH EV-miR-335 INDUCES LESS PROLIFERATION AS WELL AS INCREASED APOPTOSIS
To investigate the mechanism of miR-335-5p-meditated tumor inhibition, we assayed for Ki67 and caspase-3 in slides prepared from the tumors. As shown in Figure 7 , the expression of Ki67 was reduced in the LX2-Exo-miR group versus the LX2-Exo-nsm group, and the cleaved caspase-3 expression in LX2-Exo-miR group was increased. These data suggest that EV-miR-335-5p inhibits tumor growth in vivo through decreased proliferation as well as increased apoptosis.
UNBIASED IDENTIFICATION OF miR-335-5p DOWNSTREAM mRNA TARGETS
To determine mRNA targets of miR-335-5p in an unbiased fashion, we transfected MHCC97H and MHCC97L with miR-335-5p mimic or negative control. In addition, mouse xenograft tumors from mice treated with EV-miR-335-5p as well as control, respectively, were collected. A total of four mice tumors were used for this experiment. Specifically, two mice were used to establish MHCC97L-derived subcutaneous tumors (one tumor per mouse). One of the tumors was treated with EV-NSM and the other mouse tumor was treated with EV-miR-335-5p. In addition, two mice were used to establish MHCC97H subcutaneous tumors. Similarly, one mouse tumor was treated with EV-NSM and the other with EV-miR-335-5p. Intratumoral injections with EV-NSM or EV-miR-335-5p were performed twice a week for duration of 4 weeks. RNA from cell lines (a total of four samples) and from mouse tumors (a total of four samples) were used to identify differentially expressed mRNA species between NSM and miR-335-5p-treated samples. The Taqman Human Cancer Panels (ThermoFisher Scientific) was used. Bioinformatics analyses identified 13 genes that were consistently and uniformly downregulated in the four RNA samples treated with miR-335-5p. Of note, we used this stringent experimental approach instead of the bioinformatics-based search engine approach to confirm our report of high specificity. Given how strict the determination of these putative targets was (in vitro, Fig. 8A ,B, and in vivo, Fig.  8C ,D, each on two separate cell lines), it is likely that these targets are indeed down-regulated by miR-335-5p and involved in its downstream effects. These mRNA species are: CDC42, CDK2, CSNK1G2, EIF2C2, EIF5, LIMK1, NRG1, PLK2, RGS19, TCF3, THBS1, YBX1, and ZMYND8. The modulation of pathways downstream of miR-335 is likely to be explained, at least in part, by these trancriptomics changes. The exhaustive identification of mechanisms of miR-335 action was beyond the scope of this study.
Discussion
The vast majority of HCC cases arise in a background of liver fibrosis/cirrhosis that is rich in activated fibroblasts/stellate cells. Starting with this observation, we hypothesized that stellate cells and cancer cells can communicate. Furthermore, we posited that the communication between stellate cells and cancer cells is done in part through EVs. We found that coculturing stellate and cancer cells results in down-regulation of miR-335-5p in both cell types. Although it was not the purpose of this study to investigate the mechanisms through which this concomitant down-regulation occurs, we did not observe a similar phenomenon in cholangiocarcinoma. (8) It is attractive to hypothesize that the down-regulation of miR-335-5p is conducive to cancer development and/or homeostasis. Conversely, up-regulation of miR-335-5p in cancer cells, or in neighboring fibroblasts, should result in cancer repression. We have noted such cancer repression (invasion as well as growth) when miR-335-5p has been up-regulated either in cancer cells or in fibroblasts.
Previous work in cholangiocarcinoma demonstrates that cancer cells avidly uptake stellate cell/fibroblastderived EVs. (8) While the mechanisms of EV shuttling between cholangiocarcinoma cells and neighboring stromal cells in vivo have not been elucidated to date, this previous report argues that such process occurs and also that it can be used/adapted for therapeutics delivery to cancer cells in vivo. (8) Previously published work showed that that miR-335-5p is 1) downregulated in liver cancer cells (15) ; and 2) downregulated in activated, collagen-producing stellate cells versus inactive cells. (11) In the current study, we noted further down-regulation in both cancer cells and stellate cells upon their direct coculture. These findings suggest that shuttling of EVs and their cargo between HCC cells and surrounding stromal cells occurs, but the precise mechanisms of this process continue to be elusive. Furthermore, it is possible that, through a yet undiscovered mechanism, the symbiotic cancer cellstromal cell environment requires low levels of miR-335-5p for successful cancer genesis and development. This hypothesis is supported by our findings that upregulation of miR-335-5p in either cancer cells, or in stromal cells, is sufficient to inhibit HCC growth and/ or invasion (Figs. 2, 3, 4, and 6) .
The observation that up-regulation of miR-335-5p in fibroblasts results in neighboring cancer cell repression suggests that miR-335-5p might be shuttled between these two cell types. Indeed, when miR-335-5p was directly up-regulated in EVs and delivered to cancer cells, a similar effect was noted. Building on these observations, we verified that EVs can be used as vehicles to deliver miR-335-5p in vivo to cancer cells, as has been reported previously by our group in cholangiocarcinoma. (8) The fact that we successfully delivered EVs to cancer cells in vivo, that EV content was successfully taken up and utilized by cancer cells, and finally, that the treatment resulted in slower cancer growth suggests that EVs may indeed be used as cancer therapeutics in HCC.
To obtain an unbiased view on mRNA targets downstream of miR-335-5p, we performed a qRT-PCR screen. We used the Taqman Human Cancer . Each of the two pairs was treated with EV-NSM, and the other mouse tumor per group was treated with EVmiR-335-5p. We extracted the total RNA from the mice tumor. qRT-PCR array using the Taqman Human Cancer Panels demonstrate the down-regulation of these 13 potential mRNA targets of miR-335-5p.
Panel, which has 624 genes related to DNA repair, angiogenesis, cell adhesion, cell cycle, and apoptosis. We identified the most likely targets of miR-335-5p as CDC42, CDK2, CSNK1G2, EIF2C2, EIF5, LIMK1, NRG1, PLK2, RGS19, TCF3, THBS1, YBX1, and ZMYND8. Among these genes, CDC 42, (19, 20) CDK2, (21, 22) EIF2C2, (23, 24) EIF5, (25, 26) LIMK1, (27) NRG1, (28) PLK2, (29) RGS19, (30) TCF3, (31) THBS1, (32) as well as YBX1 (33) have been implicated in hepatocellular carcinoma, and some of them are related to invasion and metastasis. Out of these 13 downstream miR-335-5p targets, CSNK1G2 and ZMYND8 are reported here for the first time as playing a role in HCC.
In the current study, we chose to deliver EVs directly to xenografted tumors (via direct intratumor injections). Unlike in experiments performed previously in cholangiocarcinoma, (8) in this study we chose to circumvent vascular delivery of EVs to tumor site by directly injecting EVs into the tumors. The rationale was two-fold: first, we focused on the uptake of EVs by cancer cells once these EVs were delivered to the tumor mass (as opposed to focusing on concentrating EVs from the blood stream to the cancer mass), and second, there is a precedent whereby active chemotherapeutics are given to unresectable or multifocal HCC patients by intra-arterial delivery to the cancer. This method, known as trans-arterial chemoembolization, is an accepted and widely used method of HCC treatment. (34) Nonetheless, it should be noted that intratumoral injections of EVs is merely a model of cancer therapeutics delivery that does not perfectly model intravenous nor intra-arterial delivery. Therefore, further studies must identify if the best delivery method of EVs to HCC patients is via intravenous delivery, or, as in the case of trans-arterial chemoembolization, via direct delivery to the cancer mass.
There are multiple future directions stemming from this study. For example, we did not identify the causal factors resulting in the down-regulation of miR-335-5p in both stellate cells and cancers cells upon their coculture. In addition, we did not test EVs produced by other cell types to investigate whether the cargo delivery by stellate cell-produced EVs is related to the cell of origin. This aspect is important for future developments of EVs as cancer therapeutics. Finally, we did not perform an exhaustive investigation of pathways downstream of miR-335-5p. Although we took the first steps toward finding miR-335-5p targets in an unbiased fashion, further work is necessary should miR-335-5p be considered as a potential HCC therapeutic.
